Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy

NCT04002089 | Completed Phase 1 FDA Drug

• 1 other identifier: 402-C-122
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

This is a pilot, open label, single center study in 40 subjects undergoing bunionectomy. The study will assess and collect information on pharmacokinetics, pharmacodynamics, safety and efficacy of EXPAREL administered as a sciatic nerve block (in popliteal fossa). A total of 10 subjects will be enrolled in each of the 4 cohorts.

Conditions

Bunion

Outcome Measures

Primary Outcomes (8)

• Pharmacokinetic 1 (Area under the plasma concentration)

  Area under the plasma concentration-versus-time curve (AUC).

  predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1), 60(±2), 72(±2), 84(±2), 96(±3), 120(±3), 144(±3), and 168(±3) hours following block

• Pharmacokinetic 2 (Cmax)

  Maximum plasma concentration (Cmax)

  predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block

• Pharmacokinetic 3 (half-life )

  The apparent terminal elimination half-life (t1/2el).

  predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block

• Pharmacokinetic 4 (Apparent clearance)

  Apparent clearance (CL/F).

  predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block

• Pharmacokinetic 5 (volume of distribution)

  Apparent volume of distribution (Vd).

  predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block

• Pharmacokinetic 6 (Tmax)

  Time of Cmax (Tmax)

  predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block

• Pharmacodynamic 1 (duration of sensory and motor block)

  Average duration of sensory block and motor block

  up to 15 min before block, 15 min(±5 min), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1), 60(±2), 72(±2), 84(±2), 96(±3), 120(±3), 144(±3), and 168(±3) hours following block

• Pharmacodynamic 2 (duration of sensory and motor block)

  Average duration of sensory block and motor block

  up to 15 min before block, 15 min(±5min), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1), 60(±2), 72(±2), 84(±2), 96(±3), 120(±3), 144(±3), and 168(±3) hours following block

Study Arms (4)

Cohort 1 - EXPAREL

EXPERIMENTAL

A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL admixed with bupivacaine.

Drug: Exparel Injectable Product; Drug: Bupivacaine

Cohort 2 - EXPAREL

EXPERIMENTAL

A total of 10 subjects will be enrolled. Subjects in this cohort will receive 133mg of EXPAREL admixed with bupivacaine.

Drug: Exparel Injectable Product; Drug: Bupivacaine

Cohort 3 - EXPAREL

EXPERIMENTAL

A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL only

Drug: Exparel Injectable Product

Cohort 4 - bupivacaine

ACTIVE COMPARATOR

A total of 10 subjects will be enrolled. Subjects in this cohort will receive 100mg Bupivacaine only.

Drug: Bupivacaine

Interventions

Exparel Injectable Product DRUG

bupivacaine liposome injectable suspension

Cohort 1 - EXPAREL; Cohort 2 - EXPAREL; Cohort 3 - EXPAREL

Bupivacaine DRUG

1.3%, 13.3 mg/mL

Cohort 1 - EXPAREL; Cohort 2 - EXPAREL; Cohort 4 - bupivacaine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy adult male or female volunteers ages 18 or older
• American Society of Anesthesiologists (ASA) physical status 1, 2, or 3
• Able to provide informed consent, adhere to the study schedule, and complete all study assessments.
• Body Mass Index ≥18 and ≤40 kg/m2

You may not qualify if:

• Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (eg, amide-type local anesthetics, opioids, bupivacaine, NSAIDs)
• Documented history of long-term diabetes or severe peripheral vascular disease
• Renal (serum creatinine level \>2mg/dL \[176.8 μmol/L\]) or hepatic dysfunction (serum alanine or aspartame transferase \> 3 times the upper limit of normal).
• Concurrent painful physical condition that may require analgesic treatment (such as long-term, consistent use of opioids) in the post dosing period for pain and which, in the investigator's opinion may confound the post dosing assessments
• History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years
• Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study
• Previous participation in an EXPAREL study
• Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance
• Currently pregnant, nursing, or planning to become pregnant during the study
• Clinically significant medical disease that, in the opinion of the investigator, would make participation in a clinical study inappropriate. This includes any psychiatric or other conditions that would constitute a contraindication to participation in the study
• Currently on neuroleptic agent \[e.g., gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) etc.\]
• Inadequate sensory function on the foot (monofilament test)
• Chronic opioid use in the last 30 days (≥30 morphine equivalents/ day)
• In addition, the subject may be withdrawn from the study if the subject meets the following criterion during or post-surgery:
• Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that, in the opinion of the investigator, renders the subject medically unstable or complicates the subject's post-operative course

Sponsors & Collaborators

• Pacira Pharmaceuticals, Inc: lead

Study Sites (1)

First Surgical Hospital

Bellaire, Texas, 77401, United States

Location

MeSH Terms

Conditions

Bunion

Interventions

Bupivacaine

Condition Hierarchy (Ancestors)

Foot Deformities, Acquired; Foot Deformities; Musculoskeletal Diseases

Intervention Hierarchy (Ancestors)

Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Officials

• Nayana Nagaraj

  Medical Director

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 25, 2019
• First Posted: June 28, 2019
• Study Start: July 26, 2019
• Primary Completion: December 2, 2019
• Study Completion: December 2, 2019
• Last Updated: January 11, 2021

Record last verified: 2021-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)